RxDoctor Payments DataLook up a doctor →

Christian Mangrum, DO

Endocrinology, Diabetes & Metabolism · Oklahoma City, OKNPI 1568789675

Payments from drug & device makers

$53,830in general payments, 2019–2025

Across 1,145 payments — averaging $47.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$22K
  • Lilly USA, LLC$15K
  • Insulet Corporation$2K
  • Novo Nordisk$1K
  • Xeris Pharmaceuticals, Inc.$1K
  • Abbott$1K
  • plus $11K from 50 others

What the payments were for

  • Speaking & faculty fees$32,52860%
  • Travel & lodging$1,6603%
  • Food & beverage$19,56436%
  • Education$770%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$53,830 in reported general payments places this provider in the 85th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.

See all endocrinology, diabetes & metabolism providers in Oklahoma

Medicare billing

Part B allowed, 2024
$124,877
Medicare patients
615
Services billed
1,796

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide351$563,206
OzempicSemaglutide196$342,746
JardianceEmpagliflozin126$153,668
Humulin R U-500 KwikpenInsulin Regular, Human68$106,288
TrulicityDulaglutide59$89,241
Tresiba Flextouch U-200Insulin Degludec49$84,043
FarxigaDapagliflozin Propanediol63$74,460
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/757$72,908
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog101$68,771
Tresiba Flextouch U-100Insulin Degludec59$53,763
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog29$53,427
Fiasp FlextouchInsulin Aspart (Niacinamide)37$47,022
Humalog Kwikpen U-100Insulin Lispro76$29,901
Soliqua 100-33Insulin Glargine/Lixisenatide21$27,825
Novolog FlexpenInsulin Aspart74$27,497

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog$14,703$687,607464 claims
Novo NordiskOzempic, Novolog$1,432$352,644242 claims
Boehringer IngelheimJardiance$21,836$153,668126 claims
AstraZenecaFarxiga$895$74,46063 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$627$27,82521 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$177$10,285894 claims
AbbVieSynthroid$261$7,99985 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.

Other endocrinology, diabetes & metabolism in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →